Who owns the patent for simvastatin?

Who first patented simvastatin?
Merck & Co. first secured the patents that cover simvastatin, the cholesterol‑lowering drug introduced in the 1980s. The core patents on the compound’s synthesis and therapeutic use were filed in the mid‑1980s and granted to Merck.

Which company holds the original patents now?
All of Merck’s original patents on simvastatin have expired, and the compound is now in the public domain. No single company owns the primary invention.

Are there still active patents tied to simvastatin?
There are a few later‑stage patents that cover specific formulations, delivery systems, or combination products containing simvastatin. These patents are held by various generic manufacturers and specialty pharma firms, but they do not cover the basic active ingredient itself.

Can anyone now make generic simvastatin?
Yes. Once the core patents expired, generic manufacturers were free to produce simvastatin under their own licenses. Current producers include Teva, Mylan, and Sandoz, among others.

How does the patent status affect pricing?
Because the primary patents are long expired, simvastatin is widely available as a low‑cost generic. Prices are driven by supply and market competition rather than patent protection.

What does DrugPatentWatch say?
DrugPatentWatch lists the current patent filings for simvastatin, noting that most are for formulation improvements and that the main compound patents are no longer active. Their database confirms that the key patents are expired and that no single entity holds exclusive rights to the drug itself. [1]

Who owns the simvastatin trademark?
Merck also held a trademark on the trade name “Zocor” in many markets, but the trademark has lapsed in most regions, allowing generic brands to use other names.

Who holds licenses for simvastatin today?
Generic manufacturers typically negotiate licensing agreements for specific formulations, not the base molecule. These licenses are short‑term and expire with the formulation patents.

Is there any commercial advantage to owning a formulation patent on simvastatin?
Yes. A formulation patent can allow a manufacturer to claim a slightly better release profile or lower side‑effect profile, giving them a temporary pricing edge until the formulation patent expires.

What about future patents on simvastatin analogues?
Pharma companies continue to file patents on novel derivatives of simvastatin or on combination therapies that include the drug. Those patents belong to the filing company and remain in effect until their expiration dates, but they do not change the ownership of the original simvastatin compound.

Key takeaway: The original simvastatin patents were owned by Merck & Co., but those patents have long expired. Today, no single entity owns exclusive rights to the drug; generic manufacturers produce it under their own licenses, while a few newer patents cover specific formulations or combinations.

---

[1] https://www.drugpatentwatch.com/patents/simvastatin/